GlobeNewswire

Jessye Norman awarded The Twelfth Glenn Gould Prize

Dela

TORONTO, April 16, 2018 (GLOBE NEWSWIRE) -- One of the great singers of her generation, renowned for her extraordinary voice and musical versatility, American opera singer and recitalist Jessye Norman has been chosen as The Twelfth Glenn Gould Prize Laureate.  Throughout her career, the sheer size, power and luster of her voice has shared equal acclaim with that of her thoughtful music-making, innovative programming of the classics, and fervent advocacy of contemporary music.  More than forty years after making her operatic debut, Jessye Norman continues to maintain a busy performance schedule, now concentrating on recitals and concerts.

"It is with the utmost humility and gratitude that I accept this magnificent honor, The Glenn Gould Prize. I was thrilled to have answered the telephone myself and to have heard this most wonderful news firsthand! My admiration for the artistic genius of Glenn Gould began very early on in my studies and was further supported in my having had Walter Homburger as the first presenter to invite me to perform in Canada.  His work with Glenn Gould is, of course, legendary," stated Jessye Norman. "It was he who made certain that I could experience on film the music of Bach played by a master of the keyboard and intellect of the highest order. Thank you, Walter. Thanks to The Glenn Gould Foundation. To have been chosen to receive this auspicious recognition is quite simply breath-taking!"

"We had a very thorough series of discussions that helped us to gradually narrow down an impressive list of nominees, always bearing in mind Glenn Gould's legacy and impact as a unique artist," said Viggo Mortensen, Chair of The Glenn Gould Prize Jury. "The day-long winnowing process became increasingly challenging as we got down to a handful of finalists, but we were united in our admiration for The Twelfth Glenn Gould Prize Laureate, the incomparable Jessye Norman."

"All of us at The Glenn Gould Foundation are beyond thrilled at the inspired selection made by this year's jury.  Jessye Norman is undoubtedly one of the great vocal artists of our time, or any time, but so much more. Her career has provided a positive role model for countless artists coming from disadvantaged circumstances as she did and overcoming the very real racial barrier that thwarted so many careers. Her triumph is an expression of the power of art to transcend all human boundaries," said Brian Levine, Executive Director of The Glenn Gould Foundation.

Jessye Norman made her operatic debut in 1969 at the Deutsche Oper Berlin and has since won acclaim for her performances in a wide range of leading roles with the world's premier opera companies, in solo recitals and in concerts with preeminent orchestras around the globe.  Her exceptional artistry has earned her the reputation as one of the most versatile concert and operatic singers of her time.  She has more than seventy-five recordings of her eclectic repertoire to her credit. She is well known for her mastery of the music of Richard Strauss, one of Glenn Gould's favourite composers.  Given the exceptional range of her voice, she has sung the repertoire of sopranos, mezzo-sopranos and altos throughout her career.  She has also begun to sing jazz, in concert and in multi-media collaborations, and she has performed an extensive repertoire of contemporary music.

Ms. Norman is the recipient of many international awards and honours including The Kennedy Center Honor, five Grammy awards including the Grammy Lifetime Achievement Award for Classical Music, The National Medal of Arts, and her many other prestigious distinctions include honourary doctorates at more than forty colleges, universities and conservatories around the world.

Known as a devoted mentor and generous supporter of young artists and emerging talent, Ms. Norman is also admired for her humanitarian contributions and attributes her citizenship and sensitivity to the examples of community service set by her parents.  She helped to establish The Jessye Norman School of the Arts in her hometown of Augusta, Georgia and is often called upon to speak to her passionate involvement and advocacy of arts education. Ms. Norman serves on the Boards of Directors for numerous organizations including The New York Public Library, Carnegie Hall, The Dance Theatre of Harlem, and The New York Botanical Gardens.  She is national spokesperson for The Partnership for the Homeless and a lifetime member of the Girl Scouts of America.

Jessye Norman was chosen from a distinguished list of international candidates across a broad spectrum of creative disciplines, nominated by members of the general public worldwide. Ms. Norman will receive a cash award of $100,000 (CAD) and The Glenn Gould Prize statue by Canadian artist Ruth Abernethy.

Ms. Norman will choose an outstanding young artist or ensemble to receive The City of Toronto Glenn Gould Protégé Prize of $15,000 (CAD), one who embodies the qualities of creative promise, innovation and career potential demonstrated by Gould in his youth.  The recipient of the Protégé Prize will be announced later this year. Both Ms. Norman and her protégé will receive their award at a gala ceremony and their work will be honoured through a series of public events presented within the next year.

The Twelfth Glenn Gould Prize Jury was chaired by Academy Award-nominated actor, painter, poet, and musician Viggo Mortensen (United States/Denmark); Academy and Grammy Award-winning director of film, opera and theatre, and accomplished screenwriter François Girard (Canada); singer and actress Ute Lemper (Germany); writer and former Chief Justice The Right Honourable Beverley McLachlin (Canada); painter and conservationist Naeemeh Naeemaei (Iran); acclaimed soprano Sondra Radvanovsky (Canada/United States); Academy Award-winning composer and conductor Howard Shore, OC (Canada); kora virtuoso and composer Foday Musa Suso (Gambia/United States); and award-winning composer and Chairman of the China Musicians' Association Professor Ye Xiaogang (China).

About The Glenn Gould Prize
An international symbol of creative excellence, The Glenn Gould Prize is awarded biennially to a living individual for a unique lifetime contribution that has enriched the human condition through the arts.  A tribute to Glenn Gould's artistry and his multifaceted contributions to culture, the prize promotes the vital connection between artistic excellence and the transformation of lives.  With its guiding principles of Celebration, Inspiration and Transformation, The Glenn Gould Prize stands as a symbol of artistic excellence and achievement, open to all nationalities and a wide range of creative disciplines.  Past laureates include Philip Glass (2015), Robert Lepage (2013), Leonard Cohen (2011), Dr. José Antonio Abreu (2008), founder of El Sistema, Pierre Boulez (2002), Yo-Yo Ma (1999), Oscar Peterson (1993) and Lord Yehudi Menuhin (1990). For more information visit www.glenngould.ca.

 

Contact Info: Karen Lorenowicz 416-245-2475 karen.lorenowicz@gmail.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: The Glenn Gould Foundation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum